{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:30:24Z","timestamp":1781173824768,"version":"3.54.1"},"reference-count":31,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Palliative Medicine Reports"],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:p>Thanatophoric dysplasia (TD) is a rare skeletal dysplasia commonly thought to be lethal. In this case report, we discuss a nine-year-old male with TD and review his parents' decision making shortly after their son was born, the technology needed to sustain him, and his parents' perception of his quality of life. We also summarize the clinical course of published long-term survivors with TD. Pediatric Palliative Care teams, especially those conducting perinatal palliative care consultations, are often asked to support families in the face of prognostic uncertainty. Our case report and review of the literature adds to the uncertainty of prognosis in TD and suggests that pediatric palliative care providers should be wary of the label \u201clethal.\u201d<\/jats:p>","DOI":"10.1089\/pmr.2020.0016","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T17:24:18Z","timestamp":1589477058000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Should We Stop Calling Thanatophoric Dysplasia a Lethal Condition? A Case Report of a Long-Term Survivor"],"prefix":"10.1177","volume":"1","author":[{"given":"Ricki S.","family":"Carroll","sequence":"first","affiliation":[{"name":"Division of Orthogenetics, Nemours\/Alfred I. duPont Hospital for Children, Wilmington, Delaware, USA."},{"name":"Division of Palliative Medicine, Nemours\/Alfred I. duPont Hospital for Children, Wilmington, Delaware, USA."},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela L.","family":"Duker","sequence":"additional","affiliation":[{"name":"Division of Orthogenetics, Nemours\/Alfred I. duPont Hospital for Children, Wilmington, Delaware, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Schelhaas","sequence":"additional","affiliation":[{"name":"Division of Orthogenetics, Nemours\/Alfred I. duPont Hospital for Children, Wilmington, Delaware, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Little","sequence":"additional","affiliation":[{"name":"Division of Orthogenetics, Nemours\/Alfred I. duPont Hospital for Children, Wilmington, Delaware, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elissa G.","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Palliative Medicine, Nemours\/Alfred I. duPont Hospital for Children, Wilmington, Delaware, USA."},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Bober","sequence":"additional","affiliation":[{"name":"Division of Orthogenetics, Nemours\/Alfred I. duPont Hospital for Children, Wilmington, Delaware, USA."},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","unstructured":"Wilcox WR Tavormina PL Krakow D et al.: Molecular radiologic and histopathologic correlations in thanatophoric dysplasia. Am J Med Genet 1998;78:274\u2013281.","DOI":"10.1002\/(SICI)1096-8628(19980707)78:3<274::AID-AJMG14>3.0.CO;2-C"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","unstructured":"Baitner AC Maurer SG Gruen MG Di Cesare PE: The genetic basis of the osteochondrodysplasias. J Pediatr Orthop 2000;20:594\u2013605.","DOI":"10.1097\/01241398-200009000-00010"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","unstructured":"Chen CP Chern SR Shih JC et al.: Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia. Prenat Diagn 2001;21:89\u201395.","DOI":"10.1002\/1097-0223(200102)21:2<89::AID-PD21>3.0.CO;2-9"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"103603","DOI":"10.1016\/j.ejmg.2018.12.008","article-title":"Bone dysplasias in 1.6 million births in Argentina","volume":"62","author":"Duarte SP","year":"2019","unstructured":"Duarte SP, , Rocha ME, , Bidondo MP, et al.: Bone dysplasias in 1.6 million births in Argentina. Eur J Med Genet, 2019; 62:103603.","journal-title":"Eur J Med Genet"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","unstructured":"Baker KM Olson DS Harding CO Pauli RM. Long-term survival in typical thanatophoric dysplasia type 1. Am J Med Genet 1997;70:427\u2013436.","DOI":"10.1002\/(SICI)1096-8628(19970627)70:4<427::AID-AJMG18>3.0.CO;2-J"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","unstructured":"Katsumata N Kuno T Miyazaki S et al.: G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric dysplasia. Endocr J 1998;45(Suppl):S171\u2013S174.","DOI":"10.1507\/endocrj.45.Suppl_S171"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","unstructured":"Kuno T Fujita I Miyazaki S Katsumata N: Markers for bone metabolism in a long-lived case of thanatophoric dysplasia. Endocr J 2000;47(Suppl):S141\u2013S144.","DOI":"10.1507\/endocrj.47.SupplMarch_S141"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","unstructured":"MacDonald IM Hunter AG MacLeod PM MacMurray SB: Growth and development in thanatophoric dysplasia. Am J Med Genet 1989;33:508\u2013512.","DOI":"10.1002\/ajmg.1320330420"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","unstructured":"Nikkel SM Major N King WJ: Growth and development in thanatophoric dysplasia\u2014An update 25 years later. Clin Case Rep 2013;1:75\u201378.","DOI":"10.1002\/ccr3.29"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","unstructured":"Pokharel RK Alimsardjono H Takeshima Y et al.: Japanese cases of type 1 thanatophoric dysplasia exclusively carry a C to T transition at nucleotide 742 of the fibroblast growth factor receptor 3 gene. Biochem Biophys Res Commun 1996;227:236\u2013239.","DOI":"10.1006\/bbrc.1996.1495"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","unstructured":"Nakai K Yoneda K Moriue T et al.: Seborrhoeic keratosis and acanthosis nigricans in a long-term survivor of thanatophoric dysplasia. Br J Dermatol 2010;163:656\u2013658.","DOI":"10.1111\/j.1365-2133.2010.09879.x"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","unstructured":"Okajima K Asai K Niwa T et al.: Clinical and biochemical findings of a patient with thanatophoric dysplasia type I: Additional finding of dicarboxylic aciduria. Cleft Palate Craniofac J 2002;39:246\u2013248.","DOI":"10.1597\/1545-1569_2002_039_0246_cabfoa_2.0.co_2"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","unstructured":"Stensvold K Ek J Hovland AR: An infant with thanatophoric dwarfism surviving 169 days. Clin Genet 1986;29:157\u2013159.","DOI":"10.1111\/j.1399-0004.1986.tb01241.x"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","unstructured":"Tonoki H: A boy with thanatophoric dysplasia surviving 212 days. Clin Genet 1987;32:415\u2013416.","DOI":"10.1111\/j.1399-0004.1987.tb03161.x"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","unstructured":"Sawai H Oka K Ushioda M et al.: National survey of prevalence and prognosis of thanatophoric dysplasia in Japan. Pediatr Int 2019;61:748\u2013753.","DOI":"10.1111\/ped.13927"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","unstructured":"Bober MB Taylor M Heinle R Mackenzie W: Achondroplasia-hypochondroplasia complex and abnormal pulmonary anatomy. Am J Med Genet Part A 2012;158A:2336\u20132341.","DOI":"10.1002\/ajmg.a.35530"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","unstructured":"Wang DC Shannon P Toi A et al.: Temporal lobe dysplasia: A characteristic sonographic finding in thanatophoric dysplasia. Ultrasound Obstet Gynecol 2014;44:588\u2013594.","DOI":"10.1002\/uog.13337"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","unstructured":"Blaas HG Vogt C Eik-Nes SH: Abnormal gyration of the temporal lobe and megalencephaly are typical features of thanatophoric dysplasia and can be visualized prenatally by ultrasound. Ultrasound Obstet Gynecol 2012;40:230\u2013234.","DOI":"10.1002\/uog.11127"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","unstructured":"Miller E Blaser S Shannon P Widjaja E: Brain and bone abnormalities of thanatophoric dwarfism. AJR Am J Roentgenol 2009;192:48\u201351.","DOI":"10.2214\/AJR.08.1524"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","unstructured":"Knisely AS Ambler MW: Temporal-lobe abnormalities in thanatophoric dysplasia. Pediatr Neurosci 1988;14:169\u2013176.","DOI":"10.1159\/000120384"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","unstructured":"Tan AP Priego G: Thanatophoric dysplasia type 1 with tectal plate dysplasia and aqueductal stenosis. Childs Nerv Syst 2019;35:1059\u20131061.","DOI":"10.1007\/s00381-018-04035-6"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","unstructured":"Soo-Kyeong J Lee N Bae MH et al.: Chylous ascites in an infant with thanatophoric dysplasia type I with FGFR3 mutation surviving five months. Fetal Pediatr Pathol 2018;37:363\u2013371.","DOI":"10.1080\/15513815.2018.1504843"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","unstructured":"Bellus GA Bamshad MJ Przylepa KA et al.: Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): Phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. Am J Med Genet 1999;85:53\u201365.","DOI":"10.1002\/(SICI)1096-8628(19990702)85:1<53::AID-AJMG10>3.0.CO;2-F"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","unstructured":"Blomberg M Jeppesen E Skovby F Benfeldt E : FGFR3 mutations and the skin: Report of a patient with a FGFR3 gene mutation acanthosis nigricans hypochondroplasia and hyperinsulinemia and review of the literature. Dermatology 2010;220:297\u2013305.","DOI":"10.1159\/000297575"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","unstructured":"Meyers GA Orlow SJ Munro IR et al.: Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet 1995;11:462\u2013464.","DOI":"10.1038\/ng1295-462"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","unstructured":"Olney RC Prickett TCR Espiner EA et al.: C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia hypochondroplasia and thanatophoric dysplasia. J Clin Endocrinol Metab 2015;100:E355\u2013E359.","DOI":"10.1210\/jc.2014-2814"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","unstructured":"Savarirayan R Irving M Bacino CA et al.: C-type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med 2019;381:25\u201335.","DOI":"10.1056\/NEJMoa1813446"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","unstructured":"Nelson KE Hexem KR Feudtner C: Inpatient hospital care of children with trisomy 13 and trisomy 18 in the United States. Pediatrics 2012;129:869\u2013876.","DOI":"10.1542\/peds.2011-2139"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","unstructured":"Nelson KE Rosella LC Mahant S Guttmann A: Survival and surgical interventions for children with trisomy 13 and 18. JAMA 2016;316:420\u2013428.","DOI":"10.1001\/jama.2016.9819"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"e20170772","DOI":"10.1542\/peds.2017-0772","article-title":"Congenital heart surgery on in-hospital mortality in trisomy 13 and 18","volume":"140","author":"Kosiv KA","year":"2017","unstructured":"Kosiv KA, , Gossett JM, , Bai S, , Collins RT 2nd: Congenital heart surgery on in-hospital mortality in trisomy 13 and 18. Pediatrics, 2017; 140:e20170772.","journal-title":"Pediatrics"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","unstructured":"Nguyen JE Salemi JL Tanner JP et al.: Survival and healthcare utilization of infants diagnosed with lethal congenital malformations. J Perinatol 2018;38:1674\u20131684.","DOI":"10.1038\/s41372-018-0227-3"}],"container-title":["Palliative Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/pmr.2020.0016","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pmr.2020.0016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pmr.2020.0016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:54:50Z","timestamp":1777679690000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/pmr.2020.0016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,5,1]]}},"alternative-id":["10.1089\/pmr.2020.0016"],"URL":"https:\/\/doi.org\/10.1089\/pmr.2020.0016","relation":{},"ISSN":["2689-2820","2689-2820"],"issn-type":[{"value":"2689-2820","type":"print"},{"value":"2689-2820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]},"article-number":"pmr.2020.0016"}}